AVNT Stock Analysis: Avient | NYSE

Color Concentrates, Polymer Formulations, Specialty Inks, Additive Dispersions

Total Rating 65

Safety 80

Buy Signal 0.27

Specialty Chemicals
Industry Rotation: +2.7

Market Cap: 3.78B
Avg Turnover: 27.9M

Risk 3d forecast

Volatility30.4%

VaR 5^th Pctl4.96%

VaR vs Median-0.91%

Reward TTM

Sharpe Ratio0.83

Rel. Str. IBD78.9

Rel. Str. Peer Group70.2

Character TTM

Beta1.190

Beta Downside1.470

Hurst Exponent0.613

Drawdowns 3y

Max DD46.87%

CAGR/Max DD0.22

CAGR/Mean DD0.54

EPS (Earnings per Share)

EPS CAGR: 9.56%
EPS Trend: 94.4%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 1.78%
Rev. Trend: 85.2%

Last SUE: 1.75
Qual. Beats: 1

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.7 years of data

Jan -0.2% 5

Feb +2.5% 11

Mar -6.0% 12

Apr +0.3% 5

May -1.1% 8

Jun +3.5% 5

Jul -0.6% 8

Aug -0.0% 5

Sep -1.2% 19

Oct -0.8% 13

Nov +2.0% 12

Dec -0.8% 13

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AVNT Avient

Avient Corporation (NYSE: AVNT) is a global formulator of specialty material solutions headquartered in Avon Lake, Ohio, with operations spanning the United States, Canada, Mexico, Europe, South America, and Asia. Founded in 1885 and formerly known as PolyOne Corporation until its 2020 rebranding, the company operates through two reporting segments: Color, Additives and Inks, which produces custom color and additive concentrates, dispersions, and proprietary inks; and Specialty Engineered Materials, which develops specialty polymer formulations for thermoplastic processors.

The company serves a diverse range of end markets, including medical and pharmaceutical devices, food packaging, personal care and cosmetics, transportation, building products, wire and cable, textiles, appliances, and industrial applications. Avient distributes its products through a combination of direct sales personnel, distributors, and commissioned sales agents.

As a mid-cap company in the Materials sector, Avient operates within the Specialty Chemicals sub-industry, focusing on engineered polymer formulations and color/additive solutions rather than commodity chemical production. This positions the company as a value-added formulator serving manufacturers that require tailored material properties for specialized applications.

Headlines to Watch Out For

Specialty Engineered Materials demand grows from healthcare and EV applications
Color Additives margins face pressure from raw material cost volatility
Clariant Color acquisition debt paydown supports capital allocation flexibility

Piotroski VR-10 (Strict) 3.0

Net Income: 171.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.53 > 1.0
NWC/Revenue: 21.81% < 20% (prev 23.26%; Δ -1.45% < -1%)
CFO/TA 0.03 > 3% & CFO 162.9m > Net Income 171.8m
Net Debt (1.53b) to EBITDA (454.3m): 3.36 < 3
Current Ratio: 1.90 > 1.5 & < 3
Outstanding Shares: last quarter (92.2m) vs 12m ago 0.44% < -2%
Gross Margin: 32.15% > 18% (prev 32.63%; Δ -0.48% > 0.5%)
Asset Turnover: 54.89% > 50% (prev 53.07%; Δ 1.83% > 0%)
Interest Coverage Ratio: 3.10 > 6 (EBIT TTM 310.8m / Interest Expense TTM 100.3m)

Altman Z'' 2.91

A: 0.12 (Total Current Assets 1.53b - Total Current Liabilities 806.9m) / Total Assets 6.00b
B: 0.32 (Retained Earnings 1.94b / Total Assets 6.00b)
C: 0.05 (EBIT TTM 310.8m / Avg Total Assets 6.07b)
D: 0.69 (Book Value of Equity 2.44b / Total Liabilities 3.55b)
Altman-Z'' = 2.91 = A

Beneish M -2.98

DSRI: 1.03 (Receivables 553.5m/523.4m, Revenue 3.33b/3.25b)
GMI: 1.01 (GM 32.63% / 32.15%)
AQI: 0.98 (AQ_t 0.58 / AQ_t-1 0.60)
SGI: 1.02 (Revenue 3.33b / 3.25b)
TATA: 0.00 (NI 171.8m - CFO 162.9m) / TA 6.00b)
Beneish M = -2.98 (Cap -4..+1) = A

What is the price of AVNT shares?

As of October 07, 2026, the stock is trading at USD 41.49 with a total of 572,595 shares traded. Over the past week, the price has changed by +1.74%, over one month by -1.98%, over three months by +7.39% and over the past year by +31.43%.

Current recommended Stop Loss: 40.00 (which is 3.6% or 1.3 ATR below the current price).

Is AVNT a buy, sell or hold?

Avient has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy AVNT.

StrongBuy: 5
Buy: 0
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the AVNT price?

Analysts Target Price	50.9	22.6%

Avient (AVNT) - Fundamental Data Overview as of 06 October 2026

Market Cap USD = 3.78b (3.78b USD * 1.0 USD.USD)
P/E Trailing = 22.2541
P/E Forward = 11.7096
P/S = 1.1335
P/B = 1.5522
P/EG = 1.224
Revenue TTM = 3.33b USD
EBIT TTM = 310.8m USD
EBITDA TTM = 454.3m USD
Long Term Debt = 1.88b USD (from longTermDebt, last quarter)
Short Term Debt = 500k USD (from shortTermDebt, last quarter)
Debt = 1.95b USD (from shortLongTermDebtTotal, last quarter) + Leases 77.3m
Net Debt = 1.53b USD (calculated: Debt 1.95b - CCE 425.6m)
Enterprise Value = 5.30b USD (3.78b + Debt 1.95b - CCE 425.6m)
Interest Coverage Ratio = 3.10 (Ebit TTM 310.8m / Interest Expense TTM 100.3m)
EV/FCF = 97.31x (Enterprise Value 5.30b / FCF TTM 54.5m)
FCF Yield = 1.03% (FCF TTM 54.5m / Enterprise Value 5.30b)
FCF Margin = 1.64% (FCF TTM 54.5m / Revenue TTM 3.33b)
Net Margin = 5.16% (Net Income TTM 171.8m / Revenue TTM 3.33b)
Gross Margin = 32.15% ((Revenue TTM 3.33b - Cost of Revenue TTM 2.26b) / Revenue TTM)
Gross Margin QoQ = 33.54% (prev 32.17%)
Tobins Q-Ratio = 0.88 (Enterprise Value 5.30b / Total Assets 6.00b)
Interest Expense / Debt = 5.14% (Interest Expense 100.3m / Debt 1.95b)
Taxrate = 25.04% (57.3m / 228.8m)
NOPAT = 233.0m (EBIT 310.8m * (1 - 25.04%))
Current Ratio = 1.90 (Total Current Assets 1.53b / Total Current Liabilities 806.9m)
Debt / Equity = 0.80 (Debt 1.95b / totalStockholderEquity, last quarter 2.44b)
Debt / EBITDA = 3.36 (Net Debt 1.53b / EBITDA 454.3m)
Debt / FCF = 28.03 (Net Debt 1.53b / FCF TTM 54.5m)
Total Stockholder Equity = 2.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.83% (Net Income 171.8m / Total Assets 6.00b)
RoE = 7.17% (Net Income TTM 171.8m / Total Stockholder Equity 2.40b)
RoCE = 7.27% (EBIT 310.8m / Capital Employed (Equity 2.40b + L.T.Debt 1.88b))
RoIC = 4.63% (NOPAT 233.0m / Invested Capital 5.03b)
WACC = 8.02% (E(3.78b)/V(5.73b) * Re(10.17%) + D(1.95b)/V(5.73b) * Rd(5.14%) * (1-Tc(0.25)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.78 | Cagr: 0.10%
[DCF] Terminal Value 73.10% ; FCFF base≈92.6m ; Y1≈81.2m ; Y5≈65.6m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.53b = -474.2m; debt exceeds intrinsic value)
EPS Correlation: 94.44 | EPS CAGR: 9.56% | SUE: 4.0 | # QB: 1
Revenue Correlation: 85.24 | Revenue CAGR: 1.78% | SUE: 1.75 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.80 | Chg30d=+0.00% | Revisions=+70% | Analysts=7
EPS current Year (2026-12-31): EPS=3.20 | Chg30d=+0.00% | Revisions=+70% | GrowthEPS=+13.5% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=3.50 | Chg30d=+0.00% | Revisions=+70% | GrowthEPS=+9.2% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: +88% (up=21, down=0)